Table 1.
Antagonist | McN-A343 | Pilocarpine | Carbachol | |
---|---|---|---|---|
AF-DX 116 | pA2 | 7.14±0.12*,** | 6.32±0.13 | 6.41±0.08 |
Slope | 1.00±0.10 | 1.22±0.15 | 0.97±0.07 | |
n=7 | n=5 | n=7 | ||
Methoctramine | pA2 | 6.92±0.25* | 6.60±0.19* | 5.87±0.08 |
Slope | 0.97±0.16 | 0.94±0.09 | 0.99±0.07 | |
n=6 | n=6 | n=7 | ||
4-DAMP | pA2 | ND | 8.70±0.08 | 8.68±0.11 |
Slope | ND | 1.02±0.15 | 1.10±0.16 | |
n=6 | n=5 | n=5 | ||
Darifenacin | pA2 | ND | ND | 8.50±0.13 |
Slope | ND | ND | 0.82±0.11 | |
n=7 | n=6 | n=6 |
Each value represents mean±s.e.m. of the number of experiments, (n). ND: not determined. The slope indicates that of regression line obtained by Schilds plot analysis. One-way analysis of variance (ANOVA) showed that there were significant differences between the group means for AF-DX 116 (P<0.0002) and methoctramine (P<0.005). * and ** represent significantly different (P<0.05) from the corresponding value for carbachol and that for pilocarpine, respectively, which were evaluated by a post hoc Bonferroni test.